CAPRI 2 GOIM Çalışması: Biyobelirteç Odaklı, Cetuximab Temelli Bir Tedavi Rejiminin Etkinliği ve Güvenliğinin Araştırılması

Sade dilde özet

Bu çalışma, metastatik kolorektal kanser (colorectal cancer) hastalarında, biyobelirteçlere göre yönlendirilen Cetuximab temelli bir tedavi rejiminin (FOLFIRI, FOLFOX ve Irinotecan ile birlikte) etkinliğini ve güvenliğini araştırmaktadır. Çalışmaya, RAS ve BRAF genlerinde mutasyon bulunmayan (wild-type), 18 yaş ve üzeri hastalar alınmıştır. Faz 2 aşamasında yürütülmüş; şu an katılımcı almamakta ancak devam etmektedir (active, not recruiting).

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Faz 2 (Phase 2)

Durum

Devam ediyor, katılım kapalı

Sponsor

University of Campania Luigi Vanvitelli

Müdahale

Cetuximab, FOLFIRI, FOLFOX regimen, Irinotecan

Başlangıç

15.07.2021

Tahmini bitiş

15.08.2026

Ülkeler

Italy

İlgili genler

Merkezler

• Ancona, Italy
• Acquaviva delle Fonti, Italy
• Bari, Italy
• Castellana Grotte, Italy
• Benevento, Italy
• Brindisi, Italy
• Monserrato, Italy
• Catania, Italy
• Catanzaro, Italy
• San Giovanni Rotondo, Italy
• Lecce, Italy
• Tricase, Italy
• Milan, Italy
• Palermo, Italy
• Padova, Italy
• Pisa, Italy
• Potenza, Italy
• Reggio Emilia, Italy
• Ragusa, Italy
• Roma, Italy
• Roma, Italy
• Statte, Italy
• Torino, Italy
• Naples, Italy
• Naples, Italy

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

1. Histologically proven diagnosis of colorectal adenocarcinoma
2. Diagnosis of metastatic disease
3. RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and/or related metastasis
4. Measurable disease according to Response Evaluation Criteria in Solid Tumors RECIST criteria, vers.1.1)
5. Male or female patients ≥ 18 years of age
6. ECOG Performance Status 0,1
7. Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment as defined by the following parameters:

   Bone marrow:
   * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
   * Hemoglobin (Hgb) ≥ 9 g/dL
   * Platelets ≥ 100 x 109/L

   Liver function:

   • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and ALT (SGPT) ≤ 2.5 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN

   Renal function:

   • Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min
8. If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment
9. If female and of childbearing potential, or if male, agreement to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 3 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate
10. Signed informed consent obtained before screening.

Exclusion Criteria:

1. Any contraindication to the use of cetuximab, Irinotecan, 5-FU, oxaliplatin, folinic acid,bevacizumab, trifluridine-tipiracil, regorafenib
2. Active uncontrolled infections, active disseminated intravascular coagulation or history of interstitial lung disease
3. Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix
4. Pregnancy (exclusion to be ascertained by a beta hCG test)
5. Breastfeeding
6. Fertile women (\<2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception•
7. Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study, Grade III or IV heart failure (NYHA classification)
8. Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin
9. Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study
10. Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before entering the study
11. Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or during participation in the study
12. Known or clinically suspected brain metastases
13. History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea
14. Severe, non-healing wounds, ulcers or bone fractures
15. Uncontrolled hypertension
16. Marked proteinuria (nephrotic syndrome)
17. Known DPD deficiency (specific screening not required)
18. Known history of alcohol or drug abuse
19. A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study
20. Absent or restricted legal capacity